By WSJ Staff
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Consumers will now be able to access NovoCare Pharmacy through Him & Hers' platform as well as clinical support, nutrition guidance and a membership, the companies said in a statement Tuesday.
"We share a vision of what consumer-centered healthcare looks like, and this is just the first step towards delivering that future," said Andrew Dudum, chief executive and founder of Hims & Hers.
"Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk's innovative medications with Hims & Hers ability to deliver access to quality care at scale, with the goal of improving long-term outcomes for more people living with chronic disease, and doing that more affordably," said Dave Moore, executive vice president of U.S. operations and global business development and president of Novo Nordisk.
(END) Dow Jones Newswires
April 29, 2025 07:31 ET (11:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。